- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02285608
Partnership in Medication Management (PIMM) in Patients With Mood Disorders (PIMM)
Partnership in Medication Management (PIMM): The Effects of One-on-one Medication Training on Medication Adherence in Patients With Mood Disorders
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The efficacy of anti-depressants or lithium reported in clinical trials differs from clinical experience. Various factors such as non-adherence to treatment and poor tolerability to medications have been related to treatment non-response or treatment failure in mood disorders (major depressive disorder and bipolar disorder). Premature discontinuation of treatment for mood disorders is common. The long treatments, the patients' beliefs about medications, the lack of knowledge about the medication/treatment purpose, benefits, dosage, and side effects and the relationship between patient and healthcare providers affect treatment continuation.
Investigators are proposing a sequential explanatory mixed methods study to investigate a novel program for medication training in persons with mood disorders. The ultimate purpose of the program is to improve medication adherence in these persons. The primary component of the present study will be quantitative, i.e., a randomized controlled trial with 12 months of follow-up to examine the effect of one-on-one medication training, including the use of a checklist system, on medication adherence in patients with mood disorders. The training program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications. To the best of the investigators' knowledge, no research has comprehensively examined whether one-on-one medication training, as described above, may improve medication adherence in patients with mood disorders.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 4K7
- Rekrutierung
- Mood Disorders Program, St. Joseph's Healthcare Hamilton
-
Kontakt:
- Carolina Oremus, MD,PhD(c)
- Telefonnummer: 36326 +1(905) 522-1155
- E-Mail: coremus@stjoes.ca
-
Kontakt:
- Margaret C McKinnon, PhD,C.Psych.
- Telefonnummer: 36645 +1(905) 522-1155
- E-Mail: mmckinno@stjoes.ca
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- admitted to the inpatient clinic of the Mood Disorders Program, St. Joseph's Healthcare Hamilton
- with a primary diagnosis of bipolar disorder I or II, or major depressive disorder
- able to speak, read, and understand English.
Exclusion Criteria:
- cut off score on Montreal Cognitive Assessment (MOCA; clinical judgement)
- significant suicidal or homicidal risk
- a medical condition/treatment known to affect the brain
- acquired brain injury.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: PIMM/SAM
Partnership in Medication Management (PIMM): The nurse and the attending physician will meet with the patient and ask how s/he administers medication at home (i.e., blister pack).
Initial education session: the nurse will teach the patient about his/her medications, dosage, purpose, when and how to take them.
Nurse and patient will establish reminders to take his/her medication.
Following the education session, patients will be required to notify the nurse when it is time to take their medications, where their medications are, dosage, purpose and side effects.
Self-Administered Medication (SAM): Patients will transition to SAM once the clinical team feels that no further medication changes are required.
SAM is also the model that the participants will follow after discharge.
|
The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects.
The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication.
Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
Andere Namen:
|
|
Kein Eingriff: Standard Prescribing Practice(SPP)
Standard prescribing practice (SPP): medication administration will proceed as standard practice.
Patients will not receive a personalized medication training.
The nurse will administer the patient's medications.
However, patients are encouraged to ask any questions regarding his/her medications.Patients will not be provided with any tool to help them to remember when to take their medications.
The nurse will record the patient's knowledge regarding his/her medications.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Medication adherence measured by the Medication Adherence Rating Scale (MARS).
Zeitfenster: Change from baseline in the Medication Adherence Rating Scale at 2 days before discharge and 1 week, 1 month, 3 months, 6 months and 12 months post-discharge
|
Medication adherence measured by the Medication Adherence Rating Scale (MARS).
We will measure medication adherence at baseline and each follow up
|
Change from baseline in the Medication Adherence Rating Scale at 2 days before discharge and 1 week, 1 month, 3 months, 6 months and 12 months post-discharge
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time to re-hospitalization
Zeitfenster: First time re-hospitalization any point during the 12-month follow-up period
|
Investigators will compare the time to re-hospitalization between each study group.
|
First time re-hospitalization any point during the 12-month follow-up period
|
|
Costs of re-hospitalization
Zeitfenster: First time re-hospitalization any point during the 12-month follow-up period
|
Investigators will adopt a healthcare system perspective and compare the costs of first re-hospitalization between each study group.
When a participant is re-hospitalized for the first time at any point during the 12-month follow-up period, investigators will conduct a chart review of the entire re-hospitalization to identify all of the direct and indirect medical resources consumed during this re-hospitalization.
The chart review will cover the entire length of the re-hospitalization, even if this length exceeds the 12-month follow-up period for the participant in question.
|
First time re-hospitalization any point during the 12-month follow-up period
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Carolina Oremus, MD, PhD(c), McMaster University
- Hauptermittler: Sharon Simmons, RN,BScN,CPMHNc, St. Joseph's Healthcare Hamilton
- Hauptermittler: Margaret C McKinnon, PhD,C.Psych., McMaster University
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- The World Health Organization.The global burden of disease: 2004 update, Table A2: Burden of disease in DALYs by cause, sex and income group in WHO regions, estimates for 2004. Geneva, Switzerland, 2008 (accessed on: March 6, 2014).
- Health Canada. A Report on Mental Illnesses in Canada. Ottawa: Health Canada, 2002.
- World Health Organization. Adherence to Long- Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization, 2003.
- Rosa AR, Marco M, Fachel JM, Kapczinski F, Stein AT, Barros HM. Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):217-24. doi: 10.1016/j.pnpbp.2006.08.007. Epub 2006 Sep 18.
- Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP Jr, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14293-6. doi: 10.1073/pnas.2336126100. Epub 2003 Nov 13. Erratum In: Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16530.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- PIMM MDP
- PIMM Mood Disorders Program (Andere Zuschuss-/Finanzierungsnummer: Mood Disorders Program, St. Joseph/s Healthcare Hamilton)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Bipolare Störung
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SAbgeschlossenBipolar IVereinigte Staaten, Frankreich, Rumänien, Polen, Kanada, Ungarn, Japan, Korea, Republik von, Malaysia, Taiwan
-
Myriad Genetic Laboratories, Inc.University of MinnesotaAbgeschlossenMajor Depression, Bipolar I und Bipolar IIVereinigte Staaten
-
Mayo ClinicAbgeschlossenMajor Depression, Bipolar I und Bipolar IIVereinigte Staaten
-
Roxane LaboratoriesAbgeschlossenBehandlung der Bipolar-I-StörungVereinigte Staaten
-
University of Sao PauloUnbekannt
-
Mclean HospitalZurückgezogenBipolar, Manie | Bipolar, gemischter Zustand
-
Shalvata Mental Health CenterOslo University Hospital; University Hospital, Antwerp; San Raffaele University...Aktiv, nicht rekrutierendAngst | Bipolar | Depression - Major Depression | Schizophenie-StörungIsrael
-
Mayo ClinicAbgeschlossenDepression | Stimmungsschwankung | BipolarVereinigte Staaten
-
Vielight Inc.Noch keine RekrutierungBipolare Störung (BD) | Bipolar | Bipolare Störung DepressionKanada
-
Massachusetts General HospitalAktiv, nicht rekrutierendBipolarVereinigte Staaten
Klinische Studien zur PIMM/SAM
-
University of DelawareUniversity of Pennsylvania; Christiana Care Health Services; Indiana UniversityAbgeschlossenStreichelnVereinigte Staaten
-
ZetrOZ, Inc.AbgeschlossenTendinopathie | Tendinose | SehnenentzündungVereinigte Staaten
-
PfizerAbgeschlossen
-
M.D. Anderson Cancer CenterAstraZenecaRekrutierungAdenoidzystisches KarzinomVereinigte Staaten
-
Wyeth is now a wholly owned subsidiary of PfizerAbgeschlossen
-
Wyeth is now a wholly owned subsidiary of PfizerBeendetAlzheimer ErkrankungFrankreich
-
Wyeth is now a wholly owned subsidiary of PfizerAbgeschlossen
-
Wyeth is now a wholly owned subsidiary of PfizerAbgeschlossen
-
Wyeth is now a wholly owned subsidiary of PfizerAbgeschlossenAlzheimer ErkrankungVereinigte Staaten
-
Region SkaneRekrutierungSchmerz, akut | Handgelenksverletzungen | HandgelenkbruchSchweden